^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CDH17 CAR-NK cell therapy
i
Other names: CDH17 CAR-NK cell therapy, RNA-CAR-NK targeting CDH17
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Medigen Biotech
Drug class:
NK cell stimulant, CDH17 inhibitor
Related drugs:
1year
Development of allogenic nonviral RNA-based CAR-NK therapy targeting CDH17 in relapsed/refractory gastrointestinal cancer. (ASCO 2023)
Ex vivo expanded human peripheral blood NK (Magicell-NK, Medigen, Taiwan) cells were used in this study. Our findings suggest that a non-viral based CDH17 CAR-NK cell therapy could be a potential allogeneic, off-the-shelf CAR-NK therapy candidate in GI cancer and support the rationale of further investigating it in vivo and clinical trials.
IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • LAMP1 (Lysosomal Associated Membrane Protein 1) • CDH17 (Cadherin 17)
|
CDH17 CAR-NK cell therapy • CHM 2301 • Magicell-NK
Share via
